• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results

    11/13/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email

    GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025.

    Q1 2026 Financial Highlights (3 Months Ended September 30, 2025):

    • Revenue was $6.7 million, a quarterly record, compared to $4.2 million in the same quarter of the previous fiscal year, representing growth of approximately 59%.
    • Production revenue was $6.0 million, a quarterly record, compared to $2.6 million in the same quarter of the previous fiscal year, representing growth of approximately 133%.
    • Engineering revenue was $0.7 million compared to $1.6 million in the same quarter of the previous fiscal year, a decrease of 59%.
    • Gross margins were 14.2% compared to 26.6% in the same quarter of the previous fiscal year.
    • Net loss for the quarter was $(1.6) million, compared to $(1.3) million in the same quarter of the previous fiscal year.
    • Adjusted EBITDA was $(1.2) million for the quarter compared to $(1.0) million in the same quarter of the previous fiscal year.

    Recent Additional Highlights:

    • Accepted a $700,000 product development order to design and build a sub-assembly for an advanced augmented reality (AR) system.
    • Accepted a $678,000 product development agreement to develop a custom high-end borescope for jet engines. The system will include multiple configurations to measure critical components inside jet engines in the field with greater-than-1080p HD resolution in extreme environmental conditions.
    • Increased production to meet the growing demand from a top-tier aerospace company for a highly complex and specific assembly provided by POC. First quarter fiscal 2026 revenue totaled $2.5 million from this customer, a quarterly record.
    • Introduced a second production line to meet increasing demand for single-use endoscope assemblies used by a leading surgical company in their cystoscopy surgery system. First quarter fiscal 2026 revenue totaled $1.6 million from this customer, a quarterly record.

    FY 2026 Financial Guidance (Year Ended June 30, 2026):

    • The Company projects for the fiscal year 2026 revenue to exceed $25 million, which represents 31% growth over the Company's fiscal year 2025 revenue.
    • The Company projects fiscal year 2026 Adjusted EBITDA to be approximately $0.5 million compared to $(3.7) million in fiscal 2025.

    "The positive momentum continued during the first quarter as we once again reported record quarterly revenue of $6.7 million, an increase of 59% from the year ago period, driven by production deliveries against multi-year agreements with a top tier aerospace company and a surgical robotics company," commented Dr. Joe Forkey, CEO of Precision Optics. "Gross margins were impacted by lower revenue and underutilization of resources in other parts of the business during the first quarter. However, we expect overall gross margin improvements during the second and subsequent quarters."

    "Two new large development agreements coming in over the past weeks are a positive sign. The programs, one for the development of sub-assemblies for an augmented reality system and the other for a high-resolution borescope for jet engine inspection, broadens our exposure to the aerospace and defense industry as our solutions are well positioned to align with the industry's need for smaller sized optical systems"

    "We believe fiscal 2026 is set to be a very good year for POC. We look forward to the continued execution against a strong backlog, delivery of systems at improved margins, and expansion of our pipeline. We continue to remain on track with the financial guidance we previously set for the year, highlighted by fiscal year 2026 revenue growth and positive Adjusted EBITDA," Forkey concluded.

    The following table summarizes the first quarter results for the periods ended September 30, 2025, and 2024:

     Three Months
     Ended September 30
     2025

     2024

    Revenues$6,680,823  $4,197,053 
            
    Gross Profit 946,358   1,117,330 
            
    Stock Compensation Expenses 301,639   149,364 
    Other 2,239,974   2,214,907 
    Total Operating Expenses 2,541,613   2,364,271 
            
    Operating Income (Loss) (1,595,255)  (1,246,941)
        
    Net Income (Loss) (1,637,030)  (1,311,247)
            
    Income (Loss) per Share       
    Basic & Fully Diluted$(0.21) $(0.21)
            
            
    Weighted Average Common Shares Outstanding      
    Basic & Fully Diluted 7,714,701   6,216,630 
            

    Conference Call Details

    Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET.

    Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or

    (412) 317-5705.

    Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/3PyMqXG06ZY.

    Replay: A teleconference replay of the call will be available for seven days, at (877) 344-7529 or (412) 317-0088, replay access code 7772062. A webcast replay will be available at https://app.webinar.net/3PyMqXG06ZY.

    About Precision Optics Corporation

    Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

    Non-GAAP Financial Measures

    Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to the aforementioned items, Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation.

    This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

    Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

    About Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, without limitation, the Company's projections for future revenue, gross margins and Adjusted EBITDA. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

    Company Contact:

    PRECISION OPTICS CORPORATION

    22 East Broadway

    Gardner, Massachusetts 01440-3338

    Telephone: 978-630-1800

    Investor Contact:

    LYTHAM PARTNERS, LLC

    Robert Blum

    Telephone: 602-889-9700

    [email protected]

          
    PRECISION OPTICS CORPORATION, INC.

    BALANCE SHEETS

    (UNAUDITED)
          
     September 30,  June 30, 
     2025  2025 
    ASSETS       
    Current Assets:       
    Cash and cash equivalents$1,392,105  $1,773,735 
    Accounts receivable, net of allowance for credit losses of $63,804 at September 30, 2025 and $80,192 at June 30, 2025 4,187,933   4,336,730 
    Inventories, net 3,880,308   3,562,112 
    Prepaid expenses 399,630   385,390 
    Total current assets 9,859,976   10,057,967 
            
    Fixed Assets:       
    Machinery and equipment 3,406,046   3,385,958 
    Leasehold improvements 1,240,705   871,356 
    Furniture and fixtures 564,944   538,428 
      5,211,695   4,795,742 
    Less—accumulated depreciation and amortization 4,250,817   4,261,950 
    Net fixed assets 960,878   533,792 
            
    Operating lease right-to-use asset 2,513,607   141,825 
    Patents, net 226,259   232,493 
    Goodwill 8,824,210   8,824,210 
    Total other assets 11,564,076   9,198,528 
    TOTAL ASSETS$22,384,930  $19,790,287 
            
    LIABILITIES AND STOCKHOLDERS' EQUITY       
    Current Liabilities:       
    Current portion of capital lease obligation$18,383  $27,368 
    Current maturities of long-term debt 577,898   577,898 
    Accounts payable 4,008,335   2,909,100 
    Contract liabilities 2,030,772   1,821,929 
    Accrued compensation and other 899,566   764,004 
    Current portion of operating lease liability 82,341   50,995 
    Total current liabilities 7,617,295   6,151,294 
            
    Long-term debt, net of current maturities 1,144,730   1,289,205 
    Operating lease liability, net of current portion 2,699,462   90,954 
    Total liabilities 11,461,487   7,531,453 
            
    Stockholders' Equity:       
    Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 7,714,701 shares at September 30, 2025 and June 30, 2025 77,147   77,147 
    Additional paid-in capital 69,453,956   69,152,317 
    Accumulated deficit (58,607,660)  (56,970,630)
    Total stockholders' equity 10,923,443   12,258,834 
            
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$22,384,930  $19,790,287 
            



    PRECISION OPTICS CORPORATION, INC.

    STATEMENTS OF OPERATIONS

    FOR THE THREE MONTHS ENDED

    SEPTEMBER 30, 2025 AND 2024

    (UNAUDITED)
          
     Three Months

    Ended September 30,
     
     2025  2024 
    Revenues$6,680,823  $4,197,053 
            
    Cost of Goods Sold 5,734,465   3,079,723 
    Gross Profit 946,358   1,117,330 
            
    Research and Development Expenses 311,840   400,659 
    Selling, General and Administrative Expenses 2,229,773   1,963,612 
    Total Operating Expenses 2,541,613   2,364,271 
            
    Operating Loss (1,595,255)  (1,246,941)
            
    Interest Expense (41,775)  (64,306)
            
    Net Loss$(1,637,030) $(1,311,247)
            
    Loss Per Share:       
    Basic & Fully Diluted$(0.21) $(0.21)
            
    Weighted Average Common Shares Outstanding:       
    Basic & Fully Diluted 7,714,701   6,216,630 
            



    PRECISION OPTICS CORPORATION, INC.

    STATEMENTS OF STOCKHOLDERS' EQUITY

    FOR THE THREE MONTHS ENDED

    SEPTEMBER 30, 2025 AND 2024

    (UNAUDITED)
                   
     Three Month Period Ended September 30, 2025 
     Number of

    Shares
      Common

    Stock
      Additional

    Paid-in

    Capital
      Accumulated

    Deficit
      Total

    Stockholders'

    Equity
     
                   
    Balance, July 1, 2025 7,714,701  $77,147  $69,152,317  $(56,970,630) $12,258,834 
    Stock-based compensation –   –   301,639   –   301,639 
    Net loss –   –   –   (1,637,030)  (1,637,030)
    Balance, September 30, 2025 7,714,701  $77,147  $69,453,956  $(58,607,660) $10,923,443 



     Three Month Period Ended September 30, 2024 
     Number of

    Shares
      Common

    Stock
      Additional

    Paid-in

    Capital
      Accumulated

    Deficit
      Total

    Stockholders'

    Equity
     
                   
    Balance, July 1, 2024 6,073,939  $60,739  $61,197,433  $(51,190,384) $10,067,788 
    Issuance of common stock in registered direct offering 265,868   2,659   1,201,883   –   1,204,542 
    Proceeds from exercise of stock option 10,363   104   26,896   –   27,000 
    Stock-based compensation –   –   149,364   –   149,364 
    Net loss –   –   –   (1,311,247)  (1,311,247)
    Balance, September 30, 2024 6,350,170  $63,502  $62,575,576  $(52,501,631) $10,137,447 
                        



    PRECISION OPTICS CORPORATION, INC.

    STATEMENTS OF CASH FLOWS

    FOR THE THREE MONTHS ENDED

    SEPTEMBER 30, 2025 AND 2024

    (UNAUDITED)
          
     Three Months

    Ended September 30,
     
     2025  2024 
    Cash Flows from Operating Activities:       
    Net Loss$(1,637,030) $(1,311,247)
    Adjustments to reconcile net loss to net cash used in operating activities -       
    Depreciation and amortization 65,181   48,290 
    Stock-based compensation expense 301,639   149,364 
    Non-cash interest expense 4,608   4,376 
    Non-cash operating lease expense 49,322   – 
    Loss on disposal of fixed assets 34,506   – 
    Changes in operating assets and liabilities -       
    Accounts receivable, net 148,797   421,896 
    Inventories, net (318,196)  (592,521)
    Prepaid expenses (14,240)  10,889 
    Accounts payable 1,099,235   746,038 
    Contract liabilities 208,843   (65,804)
    Accrued compensation and other 135,562   270,097 
    Net cash provided by (used in) operating activities 78,227   (318,622)
            
    Cash Flows from Investing Activities:       
    Purchases of fixed assets (304,731)  (24,349)
    Proceeds from sale of fixed assets 3,000   – 
    Additional patent costs (58)  (3,750)
    Net cash used in investing activities (301,789)  (28,099)
            
    Cash Flows from Financing Activities:       
    Payments of capital lease obligations (8,985)  (11,212)
    Payments of long-term debt (149,083)  (128,315)
    Payment of debt modification costs –   (15,000)
    Payment on revolving line of credit –   (500,000)
    Proceeds from registered direct sale of common stock, net –   1,204,542 
    Gross proceeds from the exercise of stock options –   27,000 
    Net cash provided by (used in) financing activities (158,068)  577,015 
            
    Net increase(decrease) in cash and cash equivalents (381,630)  230,294 
    Cash and cash equivalents, beginning of period 1,773,735   405,278 
            
    Cash and cash equivalents, end of period$1,392,105  $635,572 
            
    Supplemental disclosure of cash flow information:       
    Operating right-of-use assets obtained in exchange for operating lease liabilities$2,632,584  $– 
    Lease improvements financed by landlord$218,750  $– 
            



    PRECISION OPTICS CORPORATION, INC.
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
    ADJUSTED EBITDA
     
     Three Months Ended
     September 30
     2025

     2024

    Net Income (loss) (GAAP)$(1,637,030) $(1,311,247)
          
    Stock based compensation 301,639   149,364 
          
    Depreciation and amortization 65,181   48,290 
          
    Interest expense 41,775   64,306 
          
    Adjusted EBITDA (non-GAAP)$(1,228,435) $(1,049,287)
          


    Primary Logo

    Get the next $POCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    SEC Filings

    View All

    SEC Form S-8 filed by Precision Optics Corporation Inc.

    S-8 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    12/3/25 4:16:06 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Precision Optics Corporation Inc.

    SCHEDULE 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/21/25 5:30:20 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Precision Optics Corporation Inc.

    10-Q - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    11/13/25 4:15:47 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results

    GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025. Q1 2026 Financial Highlights (3 Months Ended September 30, 2025): Revenue was $6.7 million, a quarterly record, compared to $4.2 million in the same quarter of the previous fiscal year, representing growth of approximately 59%.Production revenue was $6.0 million, a quarterly record, compared to $2.6 million in the same quarter of the previous fis

    11/13/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Develop Custom High-End Borescope for Jet Engines

    GARDNER, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to design and build a next generation borescope system to be used to inspect the inside of jet engines from a large aerospace and defense company. The system involves the development of a high-end, small-diameter borescope designed in multiple configurations to measure critical components inside jet engines in the field. It will deliver greater-than-1080p HD resolution performance and is engineered to withstand the e

    11/11/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots

    GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to build sub-assemblies that will support an advanced augmented reality (AR) system for US Air Force fighter pilot training, powered by POC's next-generation optical sub-assembly design and manufacturing technologies. The program aims to allow pilots to wear AR headsets while in the air in their fighter jets, simulating combat training, without the need for secondary aircraft to be present. This reduces cost and the

    11/7/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pellegrino Joseph P Jr

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 9:11:13 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Woodward Peter H

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:59 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Miclot Andrew J.

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:46 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025

    GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET. Call-in Information: Intere

    11/6/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

    GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

    5/8/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care